drug
lasmiditan
Marketedupdated 3mo agoby Eli Lilly and Co
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying lasmiditan
Patent cliff
source: FDA Orange Bookfirst barrier falls
Feb 17, 2028
~1.5 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (11)
- Jul 6, 2040formulationUS 12071423
- Jul 6, 2040formulationUS 12071423
- Dec 5, 2037compositionUS 11053214
- Dec 5, 2037compositionUS 11053214
- Dec 5, 2037compositionUS 11053214
- Jul 7, 2030method-of-use (U-2718)US 122572463.9y
- Jul 7, 2030method-of-use (U-2718)US 122572463.9y
- Jul 7, 2030method-of-use (U-2718)US 122572463.9y
- Feb 17, 2028compositionUS 74230501.5y
- Feb 17, 2028compositionUS 74230501.5y
- Feb 17, 2028compositionUS 74230501.5y
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 15m ago
Found something off?
comments(0)
5-min edit window · permanent after that